MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma

Leukemia

Volumn 28, Issue 4, 2014, Pages 880-887

  Yan, Z X ^a,b   Wu, L L ^c   Xue, K ^d   Zhang, Q L ^d   Guo, Y ^d   Romero, M ^e   Leboeuf, C ^e   Janin, A ^e   Chen, S J ^a,b   Wang, L ^a,b   Zhao, W L ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b French Chinese Laboratory of Genomic and Life Sciences Laboratory of Molecular Pathology   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

bortezomib; chemoresistance; microRNA187; MYC; peripheral T cell lymphoma; tumor progression

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; KI 67 ANTIGEN; MICRORNA; MICRORNA 187; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN KINASE B; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MICE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES;

EID: 84898410270     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.291     Document Type: Article

References (34)

1. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 2010; 24: 13-21.
2. Wang X, Werneck MB, Wilson BG, Kim HJ, Kluk MJ, Thom CS et al. TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest 2011; 121: 3834-3845.
3. Bonnet M, Loosveld M, Montpellier B, Navarro JM, Quilichini B, Picard C et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood 2011; 117: 6650-6659.
4. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y et al. Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol 2007; 85: 212-218. (Pubitemid 46686580)
5. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249-1259.
6. Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res 2012; 72: 2622-2633.
7. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-3212. (Pubitemid 36712932)
8. Naci D, El Azreq MA, Chetoui N, Lauden L, Sigaux F, Charron D et al. alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 2012; 287: 17065-17076.
9. Lee D, Shin C. MicroRNA-target interactions: new insights from genome-wide approaches. Ann N Y Acad Sci 2012; 1271: 118-128.
10. Kim JW, Mori S, Nevins JR. Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res 2010; 70: 4820-4828.
11. Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S et al. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 2012; 31: 764-775.
12. Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S et al. miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res 2012; 18: 6702-6713.
13. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008; 93: 1600-1608. (Pubitemid 351656494)
14. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009; 2009: 523-531.
15. Min DJ, Ezponda T, Kim MK, Will CM, Martinez-Garcia E, Popovic R et al. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia 2012; 27: 686-694.
16. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 2005; 65: 9906-9913. (Pubitemid 41541471)
17. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010; 115: 1026-1036.
18. Desjobert C, Renalier MH, Bergalet J, Dejean E, Joseph N, Kruczynski A et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 2011; 117: 6627-6637.
19. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)\+ and ALK-anaplastic large-cell lymphoma. Proc Natl Acad Sci USA 2010; 107: 16228-16233.
20. Zhou J, Hsieh JT. The inhibitory role of DOC-2/DAB2 in growth factor receptormediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 2001; 276: 27793-27798.
21. Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F et al. The betacatenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 2009; 69: 1867-1876.
22. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-2514.
23. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004; 3: 1133-1137. (Pubitemid 40268631)
24. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707. (Pubitemid 351565618)
25. Chow EK, Fan LL, Chen X, Bishop JM. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology 2012; 56: 1331-1341.
26. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117: 6227-6236.
27. Zheng C, Jiao X, Jiang Y, Sun S. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J Int Med Res 2013; 41: 300-306.
28. Nishioka C, Ikezoe T, Yang J, Yokoyama A. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis 2009; 14: 1108-1120.
29. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-3365.
30. Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 2012; 120: 4400-4406.
31. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012; 48: 3223-3231.
32. Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G et al. Erratum to: Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) 2012; 90: 45-54 (published erratum appears in J Mol Med (Berl) 2013; 91: 771-773).
33. Ballabio E, Armesto M, Breeze CE, Manterola L, Arestin M, Tramonti D et al. Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)? Blood Cancer J 2012; 2: e83.
34. Manfe V, Biskup E, Willumsgaard A, Skov AG, Palmieri D, Gasparini P et al. cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. PLoS One 2013; 8: e59390.